Katharina Langton

Katharina Langton

Auto-generated profile, based on publicly available information

Katharina Langton

Department of Medicine III and Institute of Clinical Chemistry and Laboratory Medicine, Universitätsklinikum Carl Gustav Carus, 01307 Dresden, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ZEZoran Erlic
Zoran Erlic
PRParminder Reel
Parminder Reel
SRSmarti Reel
Smarti Reel
LALaurence Amar
Laurence Amar
APAlessio Pecori
Alessio Pecori
FBFelix Beuschlein
Felix Beuschlein
Context: Identification of patients with endocrine forms of hypertension (EHT) (primary hyperaldosteronism [PA], pheochromocytoma/paraganglioma [PPGL], and Cushing syndrome [CS]) provides the basis to implement individualized therapeutic strategies. Targeted metabolomics (TM) have revealed promising results in profiling cardiovascular diseases and endocrine conditions associated with hypertension.Objective: Use TM to identify distinct metabolic patterns between primary hypertension (PHT) and EHT and test its discriminating ability.Methods: Retrospective analyses of PHT and EHT patients from a European multicenter study (ENSAT-HT). TM was performed on stored blood samples using liquid chromatography mass spectrometry. To identify discriminating metabolites a “classical approach” (CA) (performing a series of univariate and multivariate analyses) and a “machine learning approach” (MLA) (using random forest) were used.The study included 282 adult patients (52% female; mean age 49 years) with proven PHT (n = 59) and EHT (n = 223 with 40 CS, 107 PA, and 76 PPGL), respectively.Results: From 155 metabolites eligible for statistical analyses, 31 were identified discriminating between PHT and EHT using the CA and 27 using the MLA, of which 16 metabolites (C9, C16, C16:1, C18:1, C18:2, arginine, aspartate, glutamate, ornithine, spermidine, lysoPCaC16:0, lysoPCaC20:4, lysoPCaC24:0, PCaeC42:0, SM C18:1, SM C20:2) were found by both approaches. The receiver operating characteristic curve built on the top 15 metabolites from the CA provided an area under the curve (AUC) of 0.86, which was similar to the performance of the 15 metabolites from MLA (AUC 0.83).Conclusion: TM identifies distinct metabolic pattern between PHT and EHT providing promising discriminating performance.

20 December 2020 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
KLKatharina Langton
Katharina Langton
NTNicola Tufton
Nicola Tufton
SAScott Akker
Scott Akker
JDJaap Deinum
Jaap Deinum
GEGraeme Eisenhofer
Graeme Eisenhofer
JLJacques W.M. Lenders
Jacques W.M. Lenders
Background: Phaeochromocytoma and paraganglioma (PPGL) in pregnancy, if not diagnosed antepartum, pose a high risk for mother and child.Objective: To examine the clinical clues of antepartum and postpartum/postmortem diagnosis of PPGL.Search strategy: Case reports on PPGL in pregnancy published between 1 January 1988 and 30 June 2019 in English, German, Dutch or French.Selection criteria: Case reports containing a predefined minimum of clinical data on PPGL and pregnancy.Data collection and analysis: Two authors independently performed data extraction and assessed data quality. We calculated odds ratios (OR) (with 95% confidence intervals) and used uni‐ and multivariable logistic regression analysis.Main results: Maternal and fetal/neonatal mortalities were 9.0% (18/200) and 14.2% (29/204), respectively. Maternal mortality was 42‐fold higher with PPGL diagnosed postpartum/postmortem (17/58; 29.3%) than antepartum (1/142; 0.7%) (adjusted OR 45.9, 95% CI 5.67–370, P = 0.0003). Offspring mortality was 2.6‐fold higher with PPGL diagnosed postpartum/postmortem than antepartum (OR 3.1, 95% CI 1.38–6.91, P = 0.0044). Hypertension at admission (OR 2.29, 95% CI 1.12–4.68, P = 0.022), sweating (OR 3.14, 95% CI 1.29–7.63, P = 0.014) and a history of PPGL, a known PPGL‐associated gene mutation or adrenal mass (OR 8.87, 95% CI 1.89–41.64, P = 0.0056) were independent factors of antepartum diagnosis. Acute onset of symptoms (OR 8.49, 95% CI 3.52–20.5, P < 0.0001), initial diagnosis of pre‐eclampsia (OR 6.34, 95% CI 2.60–15.5, P < 0.0001), admission for obstetric care (OR 10.71, 95% CI 2.70–42.45, P = 0.0007) and maternal tachycardia (OR 2.72, 95% CI 1.26–5.85, P = 0.011) were independent factors of postpartum diagnosis.Conclusion: Several clinical clues can assist clinicians in considering an antenatal diagnosis of PPGL in pregnancy, thus potentially improving outcome.Tweetable Systematic review of 204 pregnant patients with phaeochromocytoma identified clinical clues for a timely antepartum diagnosis.

16 August 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
SRSmarti Reel
Smarti Reel
PRParminder Singh Reel
Parminder Singh Reel
ZEZoran Erlic
Zoran Erlic
LALaurence Amar
Laurence Amar
APAlessio Pecori
Alessio Pecori
EJEmily Jefferson
Emily Jefferson
Hypertension is a major global health problem with high prevalence and complex associated health risks. Primary hypertension (PHT) is most common and the reasons behind primary hypertension are largely unknown. Endocrine hypertension (EHT) is another complex form of hypertension with an estimated prevalence varying from 3 to 20% depending on the population studied. It occurs due to underlying conditions associated with hormonal excess mainly related to adrenal tumours and sub-categorised: primary aldosteronism (PA), Cushing’s syndrome (CS), pheochromocytoma or functional paraganglioma (PPGL). Endocrine hypertension is often misdiagnosed as primary hypertension, causing delays in treatment for the underlying condition, reduced quality of life, and costly antihypertensive treatment that is often ineffective. This study systematically used targeted metabolomics and high-throughput machine learning methods to predict the key biomarkers in classifying and distinguishing the various subtypes of endocrine and primary hypertension. The trained models successfully classified CS from PHT and EHT from PHT with 92% specificity on the test set. The most prominent targeted metabolites and metabolite ratios for hypertension identification for different disease comparisons were C18:1, C18:2, and Orn/Arg. Sex was identified as an important feature in CS vs. PHT classification.

3 March 2018 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
YAYaxin An
Yaxin An
MRManja Reimann
Manja Reimann
JMJimmy Masjkur
Jimmy Masjkur
KLKatharina Langton
Katharina Langton
MPMirko Peitzsch
Mirko Peitzsch
GEGraeme Eisenhofer
Graeme Eisenhofer

1 April 2020 in Journal of the Endocrine Society
Verified
Journal Article
Open access
TDTimo Deutschbein
Timo Deutschbein
GRGiuseppe Reimondo
Giuseppe Reimondo
GDGuido Di Dalmazi
Guido Di Dalmazi
IBIrina Bancos
Irina Bancos
Henrik FalhammarHenrik Falhammar
Henrik Falhammar
MFMartin Fassnacht
Martin Fassnacht
Objective. Several smaller studies on adrenal incidentalomas (AI) suggested an association between autonomous cortisol secretion (ACS) and mortality (Di Dalmazi Lancet Diabetes Endocrinol 2014, Debono J Clin Endocrinol Metab 2014, Patrova Endocrine 2017). However, a recent meta-analysis (9 studies, 1356 patients) could not confirm these findings (Elhassan Ann Intern Med 2019). Aim. To investigate the effects of ACS on mortality, prevalence of cardiovascular (CV) risk factors, and (CV) morbidity, in a representative cohort of AI. Design. Retrospective observational study conducted at 27 ENS@T centers from 15 countries. Methods. Inclusion criteria: AI diagnosed 1996-2015, 1 mg dexamethasone suppression test, follow-up (FU) of ≥36 months, known survival status. Exclusion criteria: clinically relevant adrenal hormone excess (i.e. Cushing’s syndrome, pheochromocytoma, primary hyperaldosteronism), known malignancy. Patient stratification: serum cortisol after dexamethasone (>5 µg/dl, ACS; 1.9-5 µg/dl, possible ACS (PACS); ≤1.8 µg/dl, non-functioning adenoma (NFA)). Definition of CV events (CVE): hospitalization due to myocardial infarction and related interventions (PTCA, surgical bypass), stroke, deep vein thrombosis, pulmonary embolism. Results. 3640 patients (57% NFA, 36% PACS, 7% ACS) were considered eligible: 64% females; median age 61 years (range 18-91); median FU 84 months (36-277) (distribution between subgroups n.s.). 352 patients died during FU. Age- and sex adjusted overall survival was significantly reduced in patients with PACS (HR 1.55; 95%CI 1.24-1.94) and ACS (1.84; 1.29-2.61). Prevalence of CV risk factors were significantly higher in PACS and ACS than in NFA (hypertension: 72, 73, 57%, p<0.0001; dyslipidemia: 42, 49, 35%, p<0.0001; diabetes: 22, 25, 17%, p<0.0001) When adjusted to relevant confounders (i.e. age, sex, CV risk factors), time to first CVE was shorter in PACS (HR 1.36; 1.07-1.73) and ACS (HR 1.62; 1.10-2.40) compared to NFA. Conclusion. PACS and ACS are associated with increased overall mortality and CV morbidity. However, to prove causality a large randomized intervention trial is required.

24 July 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
NBNikolaos G Bliziotis
Nikolaos G Bliziotis
LKLeo AJ Kluijtmans
Leo AJ Kluijtmans
GTGerjen Tinnevelt
Gerjen Tinnevelt
PRParminder Singh Reel
Parminder Singh Reel
SRSmarti Reel
Smarti Reel
HTHenri JLM Timmers
Henri JLM Timmers
Despite considerable morbidity and mortality, numerous cases of endocrine hypertension (EHT) forms, including primary aldosteronism (PA), pheochromocytoma and functional paraganglioma (PPGL), and Cushing’s syndrome (CS), remain undetected. We aimed to establish signatures for the different forms of EHT, investigate potentially confounding effects and establish unbiased disease biomarkers. Plasma samples were obtained from 13 biobanks across seven countries and analyzed using untargeted NMR metabolomics. We compared unstratified samples of 106 PHT patients to 231 EHT patients, including 104 PA, 94 PPGL and 33 CS patients. Spectra were subjected to a multivariate statistical comparison of PHT to EHT forms and the associated signatures were obtained. Three approaches were applied to investigate and correct confounding effects. Though we found signatures that could separate PHT from EHT forms, there were also key similarities with the signatures of sample center of origin and sample age. The study design restricted the applicability of the corrections employed. With the samples that were available, no biomarkers for PHT vs. EHT could be identified. The complexity of the confounding effects, evidenced by their robustness to correction approaches, highlighted the need for a consensus on how to deal with variabilities probably attributed to preanalytical factors in retrospective, multicenter metabolomics studies.